#USA #New York #Pomerantz LLP #Larimar Therapeutics #LRMR

Pomerantz Law Firm Launches Investigation into Larimar Therapeutics

Overview

On July 9, 2026, the Pomerantz Law Firm announced it is investigating claims on behalf of investors of Larimar Therapeutics, Inc., which trades on NASDAQ under the ticker LRMR. This investigation arises amid allegations of securities fraud and potential unethical business practices concerning the company's clinical trials and their reporting of results.

Key Events Leading to Investigation

The critical backdrop to this investigation includes two significant events related to Larimar's clinical trials. The first occurred on September 29, 2025, when the company issued a press release presenting data from a long-term study evaluating the efficacy of nomlabofusp for treating Friedreich's Ataxia. While Larimar described the study’s results as “positive,” the report also disclosed that seven participants experienced anaphylaxis, a serious allergic reaction. Following this revelation, the company’s stock plummeted by $1.72, a drop of 33.66%, closing at $3.38.

In a follow-up, on June 29, 2026, Larimar released additional data from the same open-label study. In this update, they confirmed the submission of the first section of their Biologics License Application (BLA), which seeks accelerated approval for nomlabofusp. While they again characterized the data as “positive,” the report warned of an ongoing safety issue, revealing that 10 out of 43 patients reported anaphylactic reactions. This prompted another decline in stock price, falling by $0.46, or 12.57%, to close at $3.20.

Understanding the Role of Pomerantz LLP

Pomerantz LLP, recognized as a leading firm in corporate, securities, and antitrust class litigation, has been instrumental in defending the rights of investors against fraudulent practices for over 85 years. The firm is synonymous with the fight for justice in cases of securities fraud, breaches of fiduciary duty, and other corporate misconduct. Under the stewardship of Abraham L. Pomerantz, the firm pioneered the field of securities class actions, and continues to represent class members who have suffered damages due to corporate wrongdoing.

Danielle Peyton, a contact at Pomerantz, has encouraged affected investors to reach out for more information, indicating a readiness to take action on behalf of those who have experienced financial losses as a result of Larimar's operations.

Implications for Investors

The ongoing investigation into Larimar Therapeutics raises significant concerns not only for current investors but also for potential future stakeholders. The revelations regarding severe allergic reactions during clinical trials may indicate deeper issues within the company’s testing protocols and reporting practices. Investors are advised to stay informed and consider the potential ramifications of these findings.

As this situation develops, the impact on Larimar’s reputation and stock performance will be closely monitored. Investors are encouraged to review their positions in light of this investigation and consider the implications of continued securities fraud claims.

For those investors affected by the events surrounding Larimar Therapeutics, reaching out to Pomerantz LLP could provide avenues for recovery and transparency in this delicate situation. Further developments will reveal more about Larimar's practices and the outcome of Pomerantz's investigation.